MUSTANG BIO, INC. (MBIO): Nasdaq/NYSE listing notice — Mustang Bio receives Nasdaq delisting notice for equity shortfall; 45 days to submit compliance plan

MUSTANG BIO, INC.

Stockholders' equity of $123,000 falls short of Nasdaq's $2.5M minimum for continued listing.
Company has until April 29, 2024 to submit a plan to regain compliance.
If plan is accepted, Nasdaq may grant a 180-day extension; otherwise Company can appeal.
Trading continues on Nasdaq under MBIO with no immediate effect on listing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

MUSTANG BIO, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 13, 2024, Mustang Bio, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Annual Report on F

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-035016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.